ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EVG Evgen Pharma Plc

0.80
0.00 (0.00%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.51 2.06M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.75p to 4.05p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.06 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.51.

Evgen Pharma Share Discussion Threads

Showing 151 to 175 of 13025 messages
Chat Pages: Latest  17  16  15  14  13  12  11  10  9  8  7  6  Older
DateSubjectAuthorDiscuss
23/11/2017
15:52
LOL

a few years.

what else can you see?

Dead people ????

Pump is over

now the dump, I am afraid

bin bag aim shares
23/11/2017
15:09
Nice free float at the moment.. Will buy on weakness.. Can see this in £ in a few years
letmepass
23/11/2017
12:45
Even close high today, selling tomorrow would crash the share price
dr sexington
23/11/2017
12:44
Letmepass

Got killed here?

Look where it was trading yesterday morning !!

dr sexington
23/11/2017
11:15
Mate news about the manufacturing to come
letmepass
23/11/2017
11:07
The Company needs to issue a statement re the share price rise, I think it will come in the next few hours.
ny boy
23/11/2017
10:47
Can't see any reason for the huge share price increase. No news
werewolfie
23/11/2017
10:36
20k buy at 29p.. That's confidence for you
letmepass
23/11/2017
10:08
Yes, I was surprised there was no comment yesterday. Timbo usually has something to say...
supernumerary
23/11/2017
10:07
Ipo 37p.. Looks like its going for it
shirley83
23/11/2017
10:01
Net cash:

Evgen had £3.86m cash on the balance sheet at 31st March 2017, and with an average cash burn of ca. £300k per month, this will be sufficient to take the company through the next 12 months

hxxp://hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/20.06.17-making-clinical-progress.pdf

euclid5
23/11/2017
09:37
Up 47% today at 0933hrs on substantial buying.
Full lowest ask of 25p being paid....whoops, lowest ask risen to 26p as I type.

Oddly quiet here, given the current interest in EVG which is being widely mentioned elsewhere.

f

fillipe
07/11/2017
13:17
A couple of interesting new bits of research;

Sulforaphane reduces YAP/∆Np63α signaling to reduce cancer stem cell survival and tumor formation



and

Autophagic cell death and premature senescence: New mechanism of 5-fluorouracil and sulforaphane synergistic anticancer effect in MDA-MB-231 triple negative breast cancer cell line



From the Abstract: Sulforaphane and 5-fluorouracil have been shown to interact synergistically in the breast cancerMDA-MB-231 cell line, resulting in a significant reduction of the number of live cells compared to alone treatments

pdt
03/11/2017
08:00
Oops rise that showed disappeared. Maybe my error
peterm10
03/11/2017
07:58
News snippet on breakfast TV about moves to speed up new drug approval. Something about simultaneous phase testing. Will try and dig out story. Could explain rise ?
peterm10
24/10/2017
14:28
New Research on the Neuroprotective affects of Sulforaphane

Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich's Ataxia

From the abstract;
The in vitro treatment of the potent Nrf2 activator sulforaphane increased Nrf2 protein levels and led to the upregulation of phase II antioxidant enzymes. The neuroprotective effects were accompanied by an increase in neurites' number and extension ....Our results provide morphological and biochemical evidence to endorse a neuroprotective strategy that may have therapeutic relevance for FA. The findings of this work reinforce the crucial importance of Nrf2 in FA and provide a rationale for using Nrf2-inducers as pharmacological agents.

pdt
07/10/2017
09:15
New research by University of East Anglia on the effects of Sulforaphane on liver cancer.

Title: Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling

From the abstract;
Collectively, these findings provide new insights into the inhibitory effect of SFN on HCC tumor angiogenesis as well as tumor growth, and indicate that SFN has potential for the prevention and treatment of HCC

pdt
02/10/2017
14:46
Thanks for the link. Nothing new but a good read. I liked the quote from Stephen Franklin of his hopes for SFX-01 turning breast cancer from a death sentence to a chronic condition for women where the cancer has spread. He must have knowledge of how the compassionate use programme is going when he made that quote, I think it has been active for 3 months now. Perhaps an update with results in December. All positive though and I wonder if other publications will pick up the story.
pdt
02/10/2017
09:53
Here's the link, need to register to read full article:

Keep taking the broccoli, says British pharma company
October 1 2017, 12:01am, The Sunday Times

martywidget
02/10/2017
09:32
Apparently a mention in yesterdays Sunday Times business section. I have not seen the article, anyone know what it says?
pdt
26/9/2017
11:31
Another good piece of research on Sulforaphane and breast cancer;

Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells



A bit disappointing that the share price is drifting lower. That will not help the inevitable fund raise. Hopefully, there will be some positive news before they complete that. I have been buying on the way down but now I have probably as many as I want to hold at this stage.

pdt
04/9/2017
13:13
I wondered about those options too.

Could it it a case that they are checking under the cushions of the sofa for some lost change?

They are forecast to have around £268K cash left at the end of March, but that figure depends on receiving £660K in tax credit from HMRC, so maybe it was friends and family helping out by cashing the options early (they still had a long way to run) in order to give them a bit more breathing space?

timbo003
03/9/2017
18:05
PDT thanks!I wondered if the options exchanged for shares were people cashing in before a fund raising
dave444
03/9/2017
09:24
dave444 - the chances of a fundraising event are high over the next few months. They run out of cash mid 2018 and need to complete their two phase 2 trials ending late 2018. In a recent interview the CEO stated more funds would be needed. However, the amount needed is small, perhaps a £1m.
pdt
02/9/2017
16:32
What are the chances of a fundraising event in the next few months?
dave444
Chat Pages: Latest  17  16  15  14  13  12  11  10  9  8  7  6  Older

Your Recent History

Delayed Upgrade Clock